NEW YORK (GenomeWeb) – Liquid biopsy firm Resolution Bioscience has maintained a tight focus over the last several years on its strategy of developing narrow, clinically focused liquid biopsy assays for use as US Food and Drug-approved companion diagnostics to guide targeted cancer therapy.
The company has been relatively quiet in what has become a crowded space in which many other firms regularly announce financing rounds and names like Guardant Health have now become publicly traded.